
Plasmapheresis Decreases Belatacept Exposure: Requires Consideration for Dose and Frequency Adjustments
Belatacept was approved for kidney transplantation (KTx) in 2011. Belatacept has a long half life (9.8 d) with a small volume of distribution (0.09 L/k). After KTx, patients may require plasmapheresis (PP). However, the effects of PP on belatacept serum concentrations have not been reported. The aim of the present report is to examine the changes in serum concentration of belatacept with each PP in between belatacept dosing.
This is a non-final version of an article published in final form in Transplantation.
Files
Metadata
Work Title | Plasmapheresis Decreases Belatacept Exposure: Requires Consideration for Dose and Frequency Adjustments |
---|---|
Access | |
Creators |
|
Keyword |
|
License | In Copyright (Rights Reserved) |
Work Type | Article |
Publisher |
|
Publication Date | October 2021 |
Publisher Identifier (DOI) |
|
Deposited | December 10, 2021 |
Versions
Analytics
Collections
This resource is currently not in any collection.